Clicebo Solutions Private Limited

We leverage our scientific leadership to engage with the sponsors and investigators to provide unique clinical research

[Clicebo Solutions Private Limited @CliceboSolution]

India’s #MedTech ecosystem is moving towards indigenous innovation and global competitiveness.

At the 18th #CIIGlobalMedTechSummit, the focus was on clinical evidence, quality, regulation and commercialisation to bring innovation to patients.

#MedTechIndia #CliceboSolutions

[Clicebo Solutions Private Limited @CliceboSolution]

Celebrating excellence at Clicebo Solutions! 🌟

Congratulations to Dilnawaz Bhati, Anjali Bhatt & Nagma Khan, our Star Performers of the Year 2025. Your dedication and outstanding contributions inspire us to keep raising the bar.

#CliceboSolutions #StarPerformer #TeamClicebo

[Clicebo Solutions Private Limited @CliceboSolution]

Celebrating Leadership & Impact!
Congratulations to Dr. @Priyaarambam14 ,on winning the Strategic Leadership Impact Awards 2026 in the 36–45 Years Category by GdPhD Foundation.
https://t.co/oAsaAWAscr
A proud recognition of impactful leadership in healthcare. 👏
#GdPhD #Clicebo

[Clicebo Solutions Private Limited @CliceboSolution]

From 1,000 patients in India to expanding evidence in Europe.

#ALCHEMYEU has enrolled 25 patients, extending the clinical evaluation of the Eternia Coronary Stent System under EU MDR 2017/745.

Congratulations to @InnvolutionH, @Fabri84Dascenzo, @Priyaarambam14 , @u_kaul & team.

[Clicebo Solutions Private Limited @CliceboSolution]

A milestone in clinical research—1,000 patients enrolled in the #ProtectIRegistry.

Strengthening real-world clinical evidence for Drug-Coated Balloon (DCB) technology. Congratulations to @Translumina_in, @Priyaarambam14 & Nagma Khan.

#ClinicalResearch #InterventionalCardiology

[Clicebo Solutions Private Limited @CliceboSolution]

From clinical trial to global scientific recognition—the #TUXEDO2 India Study highlights how strong clinical evidence advances cardiovascular care through leading conferences and peer-reviewed publications.
#ClinicalResearch #Cardiology #JACC #JAMA #ClinicalTrial #CliceboSolution

[Clicebo Solutions Private Limited @CliceboSolution]

EU MDR is now a continuous evidence-generation journey—not just a CE-marking milestone. Clinical evidence, PMCF, post-market surveillance, and evidence-driven quality systems are key to sustained market access.

#EUMDR #MedicalDevices #MedTech #ClinicalResearch #CliceboSolutions

[Clicebo Solutions Private Limited @CliceboSolution]

Proud to share that the primary endpoint analysis of the #TUXEDO2 trial is now published in #JACC. A landmark study advancing evidence for PCI in diabetic patients with multivessel CAD. Proud that Clicebo Solutions served as the CRO.
#ClinicalResearch #Cardiology #MedTech

[Clicebo Solutions Private Limited @CliceboSolution]

On #NationalDoctorsDay, Dr. Upendra Kaul writes in The Indian Express on an important question: Who heals the healers?
A thoughtful perspective on supporting the well-being of those who care for others.

#Healthcare #DoctorsDay #CliceboSolutions

https://t.co/Mfn6zD4kCz

[Clicebo Solutions Private Limited @CliceboSolution]

This #NationalDoctorsDay, we honour the physicians advancing medicine through research, innovation, and evidence.
Proud to be a clinician-driven MedTech CRO led by Dr. Upendra Kaul and Dr. Rajen Ghadiok.
#CliceboSolutions #ClinicalResearch #MedTech

[Clicebo Solutions Private Limited @CliceboSolution]

Proud to share that Dr. Upendra Kaul has been conferred the Hippocrates Legacy Award 2026 at the Times Now Doctor's Day Conclave, in recognition of his outstanding contributions to cardiology, cardiovascular research, and patient care.

#Cardiology #ClinicalResearch #DoctorsDay

[Clicebo Solutions Private Limited @CliceboSolution]

Dr. Upendra Kaul shared key insights from the #TUXEDO trials at #CCC2026.

🔹 Evolution of DES technology
🔹 Ultra-thin stent platforms
🔹 Changing perspectives on PCI in diabetes with MVD
🔹 Evidence-based antiplatelet strategies
🔹 Individualized risk assessment

[Clicebo Solutions Private Limited @CliceboSolution]

A major milestone for Team Kamal Encon Medtech and Team Clicebo!

The first patient has been successfully enrolled in the PRECISION Study (POLARIS CDE) led by Dr. Rajneesh Kapoor.

#PRECISIONStudy #POLARISCDE #DEB #ClinicalResearch #MedTech

[Clicebo Solutions Private Limited @CliceboSolution]

Proud to represent Clicebo at the 3rd #MedTechPolicyMahotsav 2026 in New Delhi.
Key discussions focused on global quality standards, clinical validation, audit readiness, and building export-ready #MedTech innovation from the ground up.

#ClinicalResearch #RegulatoryAffairs

[Clicebo Solutions Private Limited @CliceboSolution]

A proud week at #EuroPCR2026.

Dr. Upendra Kaul presented findings from the #TUXEDO2 and ALCHEMY studies, while Dr. Priyadarshini Arambam presented an e-poster on multivessel PCI outcomes.

Showcasing India-generated cardiovascular evidence on a global stage.

#ClinicalResearch

[Clicebo Solutions Private Limited @CliceboSolution]

We were pleased to participate in the DIA–KMTC MedTech Conference 2026, engaging in meaningful discussions around clinical validation, regulatory pathways, digital health, AI, and the future of MedTech in India.

#MedTech #ClinicalResearch #MedicalDevices #DIAIndia #KMTC

[Clicebo Solutions Private Limited @CliceboSolution]

Dr. Upendra Kaul presented post hoc analysis from the #TUXEDO2 study at #EuroPCR2026, highlighting that prasugrel may be preferred over ticagrelor in high bleeding risk diabetic patients with multivessel disease undergoing PCI.

#Cardiology #PCI #ClinicalResearch #DAPT

[Clicebo Solutions Private Limited @CliceboSolution]

At #EuroPCR2026, Dr. Upendra Kaul presented findings from the ALCHEMY study evaluating Everolimus eluting Biodegradable Polymer #DES with ultrathin strut thickness in an all-comer population.
The study highlighted strong safety and procedural outcomes in coronary intervention.

[Clicebo Solutions Private Limited @CliceboSolution]

Clicebo Solutions attended the AsiaIntervention Editorial Board Meeting at #EuroPCR2026 alongside Dr. Upendra Kaul and Dr. Priyadarshini Arambam.
An insightful discussion with global experts shaping the future of interventional cardiology and clinical research.
#AsiaIntervention

[Clicebo Solutions Private Limited @CliceboSolution]

PCI vs. CABG in diabetic patients with multivessel disease — the evidence is shifting.
At #EuroPCR2026, Dr. Upendra Kaul presented TUXEDO-2 trial results across 66 centres and 1,800 PCI patients, highlighting evolving evidence in coronary revascularisation.
#TUXEDO2 #PCI #CABG